Akira Toriihara1, Heying Duan1, Holly M Thompson2, Sonya Park1, Negin Hatami1, Lucia Baratto1, Alice C Fan3, Andrei Iagaru4. 1. Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5281, USA. 2. Department of Nuclear Medicine, Kaiser Permanente, Santa Clara, CA, USA. 3. Division of Oncology, Department of Medicine, Stanford University, 269 Campus Drive, Stanford, CA, 94305, USA. afan@stanford.edu. 4. Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5281, USA. aiagaru@stanford.edu.
Abstract
PURPOSE: The usefulness of positron emission tomography/computed tomography (PET/CT) using (18F)-2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid peptide [PEG3-E{c(RGDyk)}2] (18F-FPPRGD2) in patients with metastatic renal cell cancer (mRCC) has not been evaluated; therefore, we were prompted to conduct this pilot study. METHODS: Seven patients with mRCC were enrolled in this prospective study. 18F-FPPRGD2 and 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) PET/CT images were evaluated in a per-lesion analysis. Maximum standardized uptake value (SUVmax) and tumor-to-background ratio (T/B) were measured for all detected lesions, both before and after starting antiangiogenic therapy. RESULTS: Sixty lesions in total were detected in this cohort. SUVmax from 18F-FPPRGD2 PET/CT was lower than that from 18F-FDG PET/CT (4.4 ± 2.9 vs 7.8 ± 5.6, P < 0.001). Both SUVmax and T/B from 18F-FPPRGD2 PET/CT decreased after starting antiangiogenic therapy (SUVmax, 4.2 ± 3.2 vs 2.6 ± 1.4, P = 0.003; T/B, 3.7 ± 3.2 vs 1.5 ± 0.8, P < 0.001). Average changes in SUVmax and T/B were - 29.3 ± 23.6% and - 48.1 ± 28.3%, respectively. CONCLUSIONS: 18F-FPPRGD2 PET/CT may be an useful tool for monitoring early response to antiangiogenic therapy in patients with mRCC. These preliminary results need to be confirmed in larger cohorts.
PURPOSE: The usefulness of positron emission tomography/computed tomography (PET/CT) using (18F)-2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid peptide [PEG3-E{c(RGDyk)}2] (18F-FPPRGD2) in patients with metastatic renal cell cancer (mRCC) has not been evaluated; therefore, we were prompted to conduct this pilot study. METHODS: Seven patients with mRCC were enrolled in this prospective study. 18F-FPPRGD2 and 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) PET/CT images were evaluated in a per-lesion analysis. Maximum standardized uptake value (SUVmax) and tumor-to-background ratio (T/B) were measured for all detected lesions, both before and after starting antiangiogenic therapy. RESULTS: Sixty lesions in total were detected in this cohort. SUVmax from 18F-FPPRGD2 PET/CT was lower than that from 18F-FDG PET/CT (4.4 ± 2.9 vs 7.8 ± 5.6, P < 0.001). Both SUVmax and T/B from 18F-FPPRGD2 PET/CT decreased after starting antiangiogenic therapy (SUVmax, 4.2 ± 3.2 vs 2.6 ± 1.4, P = 0.003; T/B, 3.7 ± 3.2 vs 1.5 ± 0.8, P < 0.001). Average changes in SUVmax and T/B were - 29.3 ± 23.6% and - 48.1 ± 28.3%, respectively. CONCLUSIONS: 18F-FPPRGD2 PET/CT may be an useful tool for monitoring early response to antiangiogenic therapy in patients with mRCC. These preliminary results need to be confirmed in larger cohorts.
Entities:
Keywords:
18F-FDG; 18F-FPPRGD2; Antiangiogenic therapy; PET/CT; Renal cell cancer
Authors: Nadia Withofs; Nicolas Signolle; Joan Somja; Pierre Lovinfosse; Eugène Mutijima Nzaramba; Frédéric Mievis; Fabrice Giacomelli; David Waltregny; Didier Cataldo; Sanjiv S Gambhir; Roland Hustinx Journal: J Nucl Med Date: 2015-02-05 Impact factor: 10.057
Authors: Robert J Motzer; Eric Jonasch; Neeraj Agarwal; Sam Bhayani; William P Bro; Sam S Chang; Toni K Choueiri; Brian A Costello; Ithaar H Derweesh; Mayer Fishman; Thomas H Gallagher; John L Gore; Steven L Hancock; Michael R Harrison; Won Kim; Christos Kyriakopoulos; Chad LaGrange; Elaine T Lam; Clayton Lau; M Dror Michaelson; Thomas Olencki; Phillip M Pierorazio; Elizabeth R Plimack; Bruce G Redman; Brian Shuch; Brad Somer; Guru Sonpavde; Jeffrey Sosman; Mary Dwyer; Rashmi Kumar Journal: J Natl Compr Canc Netw Date: 2017-06 Impact factor: 11.908
Authors: Ambros J Beer; Sylvie Lorenzen; Stephan Metz; Ken Herrmann; Petra Watzlowik; Hans-Jürgen Wester; Christian Peschel; Florian Lordick; Markus Schwaiger Journal: J Nucl Med Date: 2007-12-12 Impact factor: 10.057
Authors: Andrei Iagaru; Camila Mosci; Bin Shen; Frederick T Chin; Erik Mittra; Melinda L Telli; Sanjiv Sam Gambhir Journal: Radiology Date: 2014-07-16 Impact factor: 11.105